OncoAlly® Comprehensive Hereditary Cancer Analysis
Use
OncoAlly® Comprehensive Hereditary Cancer Analysis is a diagnostic test designed to identify genetic variants associated with hereditary cancer. It sequences and analyzes entire genes, allowing detection of all clinically relevant variant types, including deletions, duplications, insertions, and inversions of any size. This comprehensive approach ensures high specificity and sensitivity, aiding in the identification of genetic predispositions to hereditary cancers, thereby guiding medical management and treatment decisions for patients with personal or family histories suggestive of cancer susceptibility.
Special Instructions
Not provided.
Limitations
The analysis does not fully cover the CEBPA, FOCAD, GPC3, and RUNX1 genes, leaving possible unidentifiable variants in certain regions. For PMS2 (exons 13-15), sequence changes are typically detected, but structural variant sensitivity might be reduced. Additionally, short tandem repeats in the PHOX2B gene are not reported, which may limit the test's ability to detect certain genetic nuances.
Methodology
NGS (WGS)
Biomarkers
Result Turnaround Time
14-28 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5ml
Minimum Volume
Not provided
Collection Instructions
Refer to the specific [Specimen requirements for blood](https://www.variantyx.com/resources/provider-resources/specimen-requirements/blood-specimen-requirements/).
